- Featured Product
- KD/KO Validated
c-Met (Cytoplasmic) Polyclonal antibody
c-Met (Cytoplasmic) Polyclonal Antibody for IHC, IP, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (2)
Applications
WB, IP, IHC, IF, ELISA
Conjugate
Unconjugated
Cat no : 25869-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | A431 cells, HepG2 cells |
Positive IP detected in | HeLa cells |
Positive IHC detected in | human breast cancer tissue, human colon tissue, human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:200-1:1000 |
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB |
Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
Sample-dependent, check data in validation data gallery |
Published Applications
KD/KO | See 1 publications below |
WB | See 13 publications below |
IHC | See 1 publications below |
IF | See 2 publications below |
IP | See 1 publications below |
Product Information
The immunogen of 25869-1-AP is c-Met (Cytoplasmic) Fusion Protein expressed in E. coli.
Tested Reactivity | human |
Cited Reactivity | human, mouse, rat |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | c-Met (Cytoplasmic) fusion protein Ag23140 |
Full Name | met proto-oncogene (hepatocyte growth factor receptor) |
Calculated molecular weight | 1390 aa, 155 kDa |
Observed molecular weight | 145 kDa |
GenBank accession number | BC130420 |
Gene symbol | MET |
Gene ID (NCBI) | 4233 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). The c-met receptor is a 190-kD glycoprotein consisting of a 145-kD membrane-spanning beta chain and a 50-kD alpha chain (PMID: 7806559). In Western blot, this antibody produces bands of unknown identity at 55 and 100 kDa.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for c-Met (Cytoplasmic) antibody 25869-1-AP | Download protocol |
IHC protocol for c-Met (Cytoplasmic) antibody 25869-1-AP | Download protocol |
IP protocol for c-Met (Cytoplasmic) antibody 25869-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Autophagy The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
| ||
Front Oncol SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis. | ||
Kaohsiung J Med Sci Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met. | ||
Thorac Cancer CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma. | ||
Cancer Manag Res Adipose-Derived Stem Cells Promote Proliferation and Invasion in Cervical Cancer by Targeting the HGF/c-MET Pathway. |